Evidence map›Paper›PMID 30519748›Full record

ArticleJournal of gastroenterology2019

Gut microbiota dysbiosis worsens the severity of acute pancreatitis in patients and mice.

Yin Zhu, Cong He, Xueyang Li, Yan Cai, Jinxiang Hu, Yuanhang Liao, Jianhua Zhao, Liang Xia, Wenhua He, Linmeng Liu and 5 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05480241 (Impact of Exocrine Pancreatic Insufficiency Associated With Acute Pancreatitis and Pancreatic Enzyme Replacement Therapy on Gut Microbiota, Immunological Changes and Quality of Life), which is not on this map. Cited by 167 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed, 5 pooled it
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05480241 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Impact of Exocrine Pancreatic Insufficiency Associated With Acute Pancreatitis and Pancreatic Enzyme Replacement Therapy on Gut Microbiota, Immunological Changes and Quality of Life

TypeinterventionalSponsorUnidade Local de Saúde de Coimbra, EPERan2022 to 2024Enrolled84ConditionsAcute Pancreatitis, Exocrine Pancreatic Insufficiency, Gut Microbiota, ImmunologyArmsPancreatic Enzyme Replacement Therapy, Placebo
3 · Its place in the literature

Who cites it

167 citing papers in PubMed, 5 syntheses or guidelines pooled it, 240 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Towards Microbiota-Targeted Interventions in Acute Pancreatitis: Evidence From Meta-Analysis and Mendelian Randomization.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Pooled it
  4. Pooled it
  5. Microbiome changes associated with acute and chronic pancreatitis: A systematic review.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2021
    Pooled it
  6. Trial
  7. Antibiotic-associatedGut microbes · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. The Roles of Gut Microbiota in the Pathogenesis of Acute Pancreatitis.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  12. Frequency and predictors of small intestinal bacterial overgrowth in acute pancreatitis.World journal of gastrointestinal pharmacology and therapeutics · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

107 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Yin ZhuDepartment of Gastroenterology, The First Affiliated Hospital of Nanchang University, 17 Yong Waizheng Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Cong HeDepartment of Gastroenterology, The First Affiliated Hospital of Nanchang University, 17 Yong Waizheng Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Xueyang LiDepartment of Gastroenterology, The First Affiliated Hospital of Nanchang University, 17 Yong Waizheng Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Yan CaiDepartment of Gastroenterology, The First Affiliated Hospital of Nanchang University, 17 Yong Waizheng Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Jinxiang HuShanghai Major Bio-pharm Technology Co., Ltd, Shanghai, 201203, China.
Yuanhang LiaoDepartment of Gastroenterology, The First Affiliated Hospital of Nanchang University, 17 Yong Waizheng Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Jianhua ZhaoShanghai Major Bio-pharm Technology Co., Ltd, Shanghai, 201203, China.
Liang XiaDepartment of Gastroenterology, The First Affiliated Hospital of Nanchang University, 17 Yong Waizheng Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Wenhua HeDepartment of Gastroenterology, The First Affiliated Hospital of Nanchang University, 17 Yong Waizheng Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Linmeng LiuShanghai Major Bio-pharm Technology Co., Ltd, Shanghai, 201203, China.
Chun LuoShanghai Major Bio-pharm Technology Co., Ltd, Shanghai, 201203, China.
Xu ShuDepartment of Gastroenterology, The First Affiliated Hospital of Nanchang University, 17 Yong Waizheng Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Qiang CaiDivision of Digestive Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Youxiang ChenDepartment of Gastroenterology, The First Affiliated Hospital of Nanchang University, 17 Yong Waizheng Street, Donghu District, Nanchang, 330006, Jiangxi, China.
Nonghua LuDepartment of Gastroenterology, The First Affiliated Hospital of Nanchang University, 17 Yong Waizheng Street, Donghu District, Nanchang, 330006, Jiangxi, China. lunonghua@ncu.edu.cn.
Nanchang University · CNFirst Affiliated Hospital of Nanchang University · CNEmory University · US

Funding

National Natural Science Foundation of China 81460116National Natural Science Foundation of China 81760120Science and Technology Department of Jiangxi Province 20171BBG70084
6 · The paper itself

Abstract

backgroundThe gut is implicated in the pathogenesis of acute pancreatitis (AP) and the infectious complications of AP are commonly associated with enteric bacteria, yet whether gut microbiota dysbiosis participants in AP severity remains largely unknown.

methodsWe collected clinical information and fecal samples from 165 adult participants, including 41 with mild AP (MAP), 59 with moderately severe AP (MSAP), 30 with severe AP (SAP) and 35 healthy controls (HC). The serum inflammatory cytokines and gut barrier indexes were detected. Male C57BL/6 mice with AP were established and injuries of pancreas were evaluated in antibiotic-treated mice, germ-free mice as well as those transplanted with fecal microbiota. The gut microbiota was analyzed by 16S rRNA gene sequencing.

resultsThe structure of gut microbiota was significantly different between AP and HC, and the disturbed microbiota was closely correlated with systematic inflammation and gut barrier dysfunction. Notably, the microbial composition changed further with the worsening of AP and the abundance of beneficial bacteria such as Blautia was decreased in SAP compared with MAP and MSAP. The increased capacity for the inferred pathway, bacterial invasion of epithelial cells in AP, highly correlated with the abundance of Escherichia-Shigella. Furthermore, the antibiotic-treated mice and germ-free mice exhibited alleviated pancreatic injury after AP induction and subsequent fecal microbiota transplantation in turn exacerbated the disease.

conclusionsThis study identifies the gut microbiota as an important mediator during AP and its dysbiosis is associated with AP severity, which suggests its role as potential therapeutic target.

Indexed as

Acute DiseaseAdolescentAdultAgedAged, 80 and overAnimalsCase-Control StudiesCytokinesDisease Models, AnimalDysbiosisFecal Microbiota TransplantationFemaleGastrointestinal MicrobiomeHumansMaleMiceCytokinesRNA, Ribosomal, 16SAcute pancreatitisAntibiotic treatmentFecal microbiota transplantationGut microbiotaIntestinal barrier

Identifiers

PMID30519748
OpenAlexW2902304754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.